Idelalisib

Results: 8



#Item
1Interim statement from the BCSH CLL Guidelines Panel George A Follows1, Adrian Bloor2, Claire Dearden3, Steve Devereux4, Christopher P Fox5, Peter Hillmen6, Ben Kennedy7, Helen McCarthy8, Nilima Parry-Jones9, Piers EM Pa

Interim statement from the BCSH CLL Guidelines Panel George A Follows1, Adrian Bloor2, Claire Dearden3, Steve Devereux4, Christopher P Fox5, Peter Hillmen6, Ben Kennedy7, Helen McCarthy8, Nilima Parry-Jones9, Piers EM Pa

Add to Reading List

Source URL: www.bcshguidelines.com

Language: English - Date: 2015-07-22 04:38:28
2Microsoft Word - AMNOG-frühe NB-Idelalisib-Stellungnahme-AkdÄ-final

Microsoft Word - AMNOG-frühe NB-Idelalisib-Stellungnahme-AkdÄ-final

Add to Reading List

Source URL: www.akdae.de

Language: German - Date: 2016-08-19 18:04:46
    3Chairman’s Note Idelalisib the is first agent to target the phosphatidylinositol-3-kinase (PI3K) pathway and the second oral agent approved by the FDA, in July 2014, for treatment of relapsed/refractory chronic lymphoc

    Chairman’s Note Idelalisib the is first agent to target the phosphatidylinositol-3-kinase (PI3K) pathway and the second oral agent approved by the FDA, in July 2014, for treatment of relapsed/refractory chronic lymphoc

    Add to Reading List

    Source URL: gotoper-com.s3.amazonaws.com

    Language: English - Date: 2015-08-06 13:19:29
      4This is an electronically controlled document. User is responsible to verify and use the current revision. GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a

      This is an electronically controlled document. User is responsible to verify and use the current revision. GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a

      Add to Reading List

      Source URL: www.gilead.com

      Language: English - Date: 2014-07-23 23:05:41
      5This is an electronically controlled document. User is responsible to verify and use the current revision. GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a

      This is an electronically controlled document. User is responsible to verify and use the current revision. GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a

      Add to Reading List

      Source URL: www.gilead.com

      Language: English - Date: 2014-07-23 17:05:40
      6Pharmacology Update Idelalisib (Zydelig) Hien C. Tang, PharmD, James YC Shen, MD, and Betty M. Chan, PharmD, BCOP Abstract

      Pharmacology Update Idelalisib (Zydelig) Hien C. Tang, PharmD, James YC Shen, MD, and Betty M. Chan, PharmD, BCOP Abstract

      Add to Reading List

      Source URL: gotoper-com.s3.amazonaws.com

      Language: English - Date: 2015-08-06 13:19:37
        7idelalisib 100mg and 150mg tablets (Zydelig®) Gilead Sciences Ltd. SMC No[removed]February 2015

        idelalisib 100mg and 150mg tablets (Zydelig®) Gilead Sciences Ltd. SMC No[removed]February 2015

        Add to Reading List

        Source URL: www.scottishmedicines.org.uk

        Language: English
        8HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZYDELIG safely and effectively. See full prescribing information for ZYDELIG. ZYDELIG® (idelalisib) tablets, for or

        HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZYDELIG safely and effectively. See full prescribing information for ZYDELIG. ZYDELIG® (idelalisib) tablets, for or

        Add to Reading List

        Source URL: www.accessdata.fda.gov

        Language: English - Date: 2014-07-23 15:40:49